Company Overview More
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
CEO: Musunuri M.B.A., Ph.D., MBA, Shankar
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > OCGN Ocugen > Detailed Quotes

OCGN Ocugen

7.670+0.140+1.86%
Close 09/27 17:36 ET
7.500-0.17-2.22%
Post Mkt Price 09/27 17:40 ET
High
7.950
Open
7.590
Turnover
81.10M
Low
7.540
Prev.Close
7.530
Volume
10.51M
Market Cap
1.52B
P/E(TTM)
Loss
52Wk High
18.770
Shares
198.76M
P/E
Loss
52Wk Low
0.250
H Mkt Cap
1.48B
Bid-Ask Ratio
-96.83%
Historical High
778.200
H Shares
192.51M
Vol. Ratio
1.15
Historical Low
0.170
Dividend TTM
--
Div Yield TTM
--
P/B
13.09
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
5.46%
Amplitude
5.45%
Avg Price
7.718
Min Trading Unit
1
Float Market Cap
1.48B
Bid-Ask Ratio
-96.83%
Historical High
778.200
Float
192.51M
Vol. Ratio
1.15
Historical Low
0.170
Dividend TTM
--
P/B
13.09
Dividend LFY
--
Turnover Ratio
5.46%
Amplitude
5.45%
Avg Price
7.718
Min Trading Unit
1
Price Forecast

Loading...

News